Cover Image
市場調查報告書

惡性肋膜間質細胞瘤:全球臨床實驗趨勢

Malignant Pleural Mesothelioma Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 299725
出版日期 內容資訊 英文 178 Pages
訂單完成後即時交付
價格
Back to Top
惡性肋膜間質細胞瘤:全球臨床實驗趨勢 Malignant Pleural Mesothelioma Global Clinical Trials Review, H2, 2017
出版日期: 2017年12月28日 內容資訊: 英文 178 Pages
簡介

本報告提供惡性肋膜間質細胞瘤相關臨床研究最新趨勢相關分析,以疾病概要為首,彙整G7各國·E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:惡性肋膜間質細胞瘤臨床實驗數量的腫瘤臨床實驗數量比率

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:惡性肋膜間質細胞瘤臨床實驗數量的腫瘤臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

按評估項目臨床實驗數量

一定期間所採用的受驗人數

贊助商的各類型臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 惡性肋膜間質細胞瘤治療藥

有潛力的藥劑

最新臨床實驗新聞:惡性肋膜間質細胞瘤

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4758CTIDB

GlobalData's clinical trial report, "Malignant Pleural Mesothelioma Global Clinical Trials Review, H2, 2017" provides an overview of Malignant Pleural Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Pleural Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Malignant Pleural Mesothelioma Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Malignant Pleural Mesothelioma 30
  • Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews 30
  • Sep 27, 2017: Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer 30
  • Clinical Trial Profile Snapshots 32

Appendix 175

  • Abbreviations 175
  • Definitions 175
  • Research Methodology 176
  • Secondary Research 176
  • About GlobalData 177
  • Contact Us 177
  • Disclaimer 177
  • Source 178

List of Tables

List of Tables

  • Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2017* 15
  • Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Malignant Pleural Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Malignant Pleural Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2017* 18
  • Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Malignant Pleural Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Malignant Pleural Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Malignant Pleural Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Malignant Pleural Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
Back to Top